The U.S. Food and Drug Administration (FDA) on August 27, 2026, approved updated COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Sanofi for the 2026-27 immunization season, targeting the dominant XFG subvariant of the JN.1 strain. The approvals cover four vaccines in total: Moderna’s mNEXSPIKE and Spikevax, Pfizer-BioNTech’s Comirnaty, and Sanofi’s protein-based shot. All vaccines are authorized for adults 65 and older and individuals aged 12–64 with underlying health conditions that increase severe COVID-19 risk, including obesity, diabetes, asthma, cancer, immune deficiencies, and pregnancy.
The FDA’s decision follows guidance from an advisory panel recommending updated vaccines to better match circulating strains. While the agency did not issue a formal press release, manufacturers confirmed availability for the upcoming immunization season. COVID-19 infections are growing or likely growing in 47 states, according to the Centers for Disease Control and Prevention (CDC), though overall spread remains low. The CDC’s COVID dashboard notes that new strain data is limited due to low sequencing submissions.
Vaccine uptake has declined significantly in recent years, with 17.5% of adults and 10% of children receiving an updated shot in late 2025 or early 2026. The FDA approved the vaccines under a single-arm study design, waiving placebo-controlled trials due to operational challenges. Regulators estimated that 30–60% of Americans have conditions qualifying them for vaccination, though doctors may still administer vaccines off-label to others.
The approvals come as public health officials emphasize the need for updated immunizations ahead of potential seasonal surges. The FDA and Department of Health and Human Services (HHS) did not respond to requests for comment.